AnaptysBio Seals Pact With Merck

Anonymous User | Login

Published: 08-Feb-2010

AnaptysBio has entered into a strategic collaboration with Merck & Co, through an affiliate, to develop novel antibody therapeutics for a specified disease target.

As per the agreement, AnaptysBio is likely to be responsible for generating new antibodies to a specified disease target, using its proprietary somatic hypermutation (SHM) technology platform.

Merck is expected to receive worldwide rights to develop and commercialise antibodies optimised by AnaptysBio. AnaptysBio has received an upfront sum and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.

Tom Smart, chairman and CEO of AnaptysBio, said: "Our SHM-Platform generates antibodies in a human-like manner that recapitulates in the laboratory what the body naturally does when creating antibodies to fight disease. And this is achieved without the constraints and limitations often imposed by the body which can limit success. The platform provides a powerful new approach for the generation of antibodies to meet challenging therapeutic design goals.”

GSK Forms New Specialized R&D Unit

GSK has established a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Marc Dunoyer, president of Asia Pacific an ...

GSK Names New President Of GSK Japan

GlaxoSmithKline (GSK) has appointed Philippe Fauchet as president of GSK Japan. Mr Fauchet will report to Marc Dunoyer, who takes the new role as chairman of GSK Japan. M ...

Study Shows Lilly Cymbalta Helpful In Reducing Chronic Low Back Pain

Eli Lilly and Company has reported a new study, where 60mg of Cymbalta (duloxetine HCl) taken once daily reduced chronic low back pain, as measured by the Brief Pain Inve ...

Apeiron Licenses Enzyme Biotherapeutic Rights To GSK

Apeiron Biologics (Apeiron) has signed an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), ...

Starpharma Forms Drug Delivery Collaboration With Lilly

Starpharma has announced the signing of a new agreement with Eli Lilly, under which Starpharma’s dendrimer drug delivery technology will be applied to enhance compounds i ...

Sanofi-aventis To Establish New Consumer Healthcare JV In China

Sanofi-aventis has signed agreements with Minsheng Pharmaceutical to form a new consumer healthcare joint venture (JV). Sanofi-aventis will obtain a majority equity stake ...

Flexion Enters Into Agreements With Four Pharma Majors

Flexion Therapeutics (Flexion) has signed agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds along with gaining inv ...

GSK Receives FDA Approval For Lamictal XR

The FDA has approved GlaxoSmithKline's (GSK) Lamictal XR (lamotrigine) extended-release tablets as once-a-day, add-on therapy for epilepsy in patients 13 years and older, ...

GSK Gets Accelerated FDA Approval For Tykerb

The FDA has granted accelerated approval to GlaxoSmithKline (GSK) for a new combination regimen using Tykerb (lapatinib) as a first-line, all-oral treatment for women wit ...

GSK Reports Publication Of Rotavirus Vaccine Trial Results

The New England Journal of Medicine (NEJM) has published the first study demonstrating that Rotarix, GlaxoSmithKline’s (GSK) rotavirus vaccine, prevented severe rotavirus ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://drugdiscovery.pharmaceutical-business-review.com/news/anaptysbio_seals_pact_with_merck_100208/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

BaseCon

IT Pharma Solutions ...

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company engaged in ...

Johnson & Johnson

Johnson & Johnson (J&J) is engaged in the manufacture and sales of broad range of healt ...

Novartis AG

Novartis AG (Novartis) is engaged in the research, development, manufacturing and marke ...

Suppliers Product News

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750